Anavex Life Sciences Corp (AVXL)

[Gator328]

“Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.”

From a March 10, 2014 press release that Blarcamesine may treat ALS.

My gut feeling is that this is the mystery indication it’s working on. I can see why the optics would be bad to announce an ALS trial while Alzheimer’s is still going on. People would assume the worst about bad data and a pivot.

If Blarcamesine works for Alzheimer’s, still a big unknown at this point, announcing an ALS trial will be received much more favorably and will boost the share price significantly. Smart strategy by Dr. Missling to save some of his PR ammo.